Table 3. Most frequently reported suspected adverse reactions (with reporting rates  ≥ 1% ) by age group and time of onset, United Kingdom and Finland, 2015/16 (n = 2,029).

Preferred term	Time of onset
	≤ 7 days				> 7 days			Total
	n	%		CI	n	%	CI	n	%	CI
Vaxigrip (n = 1,012)
6 months to < 6 years (n = 496)
Cough	5	1.0		0.1–1.9	0			5	1.0	0.1–1.9
Pyrexia	7	1.4		0.4–2.4	1	0.2	0.0–1.1	8	1.6	0.5–2.7
Rhinorrhoea	5	1.0		0.1–1.9	1	0.2	0.0–1.1	6	1.2	0.2–2.2
≥ 6 to < 13 years (n = 111)
Vaccination site erythema	2	1.8		0.2–6.4	0			2	1.8	0.2–6.4
≥ 13 to < 18 years (n = 19)
	No data reported for this group
≥ 18 to ≤ 65 years (n = 149)
	No suspected AR ≥ 1% of total reported for this group
> 65 years (n = 237)
Cough	3	1.3		0.3–3.7	1	0.4	0.0–2.3	4	1.7	0.5–4.3
Fatigue	2	0.8		0.1–3.0	1	0.4	0.0–2.3	3	1.3	0.3–3.7
Headache	3	1.3		0.3–3.7	1	0.4	0.0–2.3	4	1.7	0.5–4.3
Influenza-like illness	5	2.1		0.3–3.9	0			5	2.1	0.3–3.9
Malaise	3	1.3		0.3–3.7	2	0.8	0.1–3.0	5	2.1	0.3–3.9
Nasopharyngitis	3	1.3		0.3–3.7	0			3	1.3	0.3–3.7
Oropharyngeal pain	2	0.8		0.1–3.0	1	0.4	0.0–2.3	3	1.3	0.3-3.7
Intanza b 15 µg (n = 1,017)
Vaccination site pain	10		1.0	0.4–1.6	0			10	1.0	0.4-1.6

AR: adverse reaction; CI: confidence interval.

^a Not all numbers add up as vaccinees could report suspected AR in both time intervals.

^b All Intanza 15 µg vaccinees were ≥ 60 years-old.